Alder BioPharmaceuticals

Lundbeck has completed the acquisition of Alder Biopharmaceuticals – a company committed to transforming migraine treatment and prevention.

The acquisition of Alder Biopharmaceuticals will expand Lundbeck’s treatment portfolio into migraine prevention and represents a major step in the execution of our Expand and Invest to Grow strategy. We can now take part in helping the migraine community where so much unmet need remains.

Read the Press Release here.

Find out more about Migraine here.


Dorte Arnbjerg

Dorte Arnbjerg

Lundbeck Integration Lead

Alder Biopharmaceuticals

11804 North Creek Parkway South, Bothell, WA 98011


+1 (425) 205 - 2900 

Cookie Policy
You have chosen to leave Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on